Physician profile
Kevin Griffiths
NPI 1932259702
$179,600.03
in general payments reported to CMS, 2019-2025
32 companies · $31K in 2025
The $31K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,076 · 2020: $5,842 · 2021: $32K · 2022: $34K · 2023: $37K · 2024: $37K · 2025: $31K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $38K · Travel and Lodging: $20K · Honoraria: $19K · Consulting Fee: $17K · Food and Beverage: $9,845 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $1,200 · Education: $122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $37,943.75 |
| Travel and Lodging | $19,904.51 |
| Honoraria | $19,250.00 |
| Consulting Fee | $16,900.00 |
| Food and Beverage | $9,844.70 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $1,200.00 |
| Education | $122.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $67,522.72 | 2019-2025 | Veltassa, Korsuva |
| Fresenius USA Marketing, INC. | $50,266.76 | 2019-2025 | Velphoro, Korsuva, Velphoro |
| Amgen INC. | $28,322.69 | 2019-2025 | Tavneos, Parsabiv, Krystexxa |
| Nxstage Medical, INC. | $26,664.15 | 2021-2024 | Nxstage System One |
| Astrazeneca Pharmaceuticals LP | $982.15 | 2019-2025 | Farxiga, Lokelma |
| Novo Nordisk INC | $797.90 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $605.52 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $593.61 | 2019-2025 | |
| Akebia Therapeutics INC | $464.79 | 2020-2025 | Auryxia, Vafseo |
| Opko Pharmaceuticals, LLC | $421.97 | 2019-2024 | Rayaldee |
| Ardelyx, INC. | $412.07 | 2024-2025 | Ibsrela |
| Travere Therapeutics, INC. | $403.08 | 2022-2025 | |
| Aurinia Pharma U.S., INC. | $318.71 | 2022-2025 | Lupkynis |
| Calliditas Therapeutics US INC. | $293.29 | 2022-2025 | Tarpeyo |
| Lilly USA, LLC | $254.01 | 2020-2025 | Jardiance, Zepbound |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $218.75 | 2020-2025 | Jynarque |
| Mallinckrodt Enterprises LLC | $159.07 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $148.95 | 2020-2025 | Jardiance |
| Horizon Therapeutics Plc | $143.18 | 2019-2023 | Krystexxa |
| Mallinckrodt Hospital Products INC. | $95.18 | 2020-2021 | |
| Glaxosmithkline, LLC. | $79.69 | 2022-2023 | Benlysta |
| Vertex Pharmaceuticals Incorporated | $73.24 | 2022 | |
| Ani Pharmaceuticals, INC. | $66.64 | 2025 | Purified Cortrophin Gel |
| Arbor Pharmaceuticals, INC. | $62.74 | 2019-2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $45.91 | 2025 | |
| Merck Sharp & Dohme LLC | $42.17 | 2021 | |
| Azurity Pharmaceuticals, INC. | $41.57 | 2023 | Edarbi |
| Alexion Pharmaceuticals, INC. | $25.29 | 2024 | Ultomiris |
| Regeneron Healthcare Solutions, INC. | $25.26 | 2019 | |
| Genzyme Corporation | $18.75 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.72 | 2019 | |
| Hikma Pharmaceuticals USA | $14.50 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Griffiths listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.